Cargando…

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer

With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Shengxiu, Wang, Liang, Sun, Yan, Du, Huakun, Yu, Xiaomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616240/
https://www.ncbi.nlm.nih.gov/pubmed/37915573
http://dx.doi.org/10.3389/fimmu.2023.1270828
_version_ 1785129350251675648
author He, Shengxiu
Wang, Liang
Sun, Yan
Du, Huakun
Yu, Xiaomin
author_facet He, Shengxiu
Wang, Liang
Sun, Yan
Du, Huakun
Yu, Xiaomin
author_sort He, Shengxiu
collection PubMed
description With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about immunotherapy re-challenge in patients with renal clear cell cancer who had irAE in the initial ICI therapy. In this study, we reported the case of a patient with advanced renal clear cell cancer who developed serious irAEs but also achieved a partial remission of tumor after ICI combined with pazopanib in the first-line treatment. After intravenous methylprednisolone therapy for two weeks, the patient fully recovered from treatment-related toxicities. After a multidisciplinary treatment (MDT) discussion and a communication with the patient, the decision was made to undergo a new fully humanized programmed death 1 (PD-1) agent, zimberelimab, combined with pazopanib for immune restart therapy. After two cycles of treatment, the patient demonstrated a partial response (PR), and the disease remained in continuous remission without any irAE at our last follow-up after 14 months’ treatment. Re-challenging with immunotherapy after irAEs is an emerging strategy that offers the potential for additional clinical benefits to previously responding patients. However, careful patient selection and monitoring are essential to maximize the safety and efficacy of this approach.
format Online
Article
Text
id pubmed-10616240
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106162402023-11-01 Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer He, Shengxiu Wang, Liang Sun, Yan Du, Huakun Yu, Xiaomin Front Immunol Immunology With the rapidly evolving of immune checkpoint inhibitors (ICIs), it has shown remarkable clinical benefits in treating various cancers. However, immune-related adverse events (irAEs) remain a significant challenge in the management of patients undergoing immunotherapy. There are limited data about immunotherapy re-challenge in patients with renal clear cell cancer who had irAE in the initial ICI therapy. In this study, we reported the case of a patient with advanced renal clear cell cancer who developed serious irAEs but also achieved a partial remission of tumor after ICI combined with pazopanib in the first-line treatment. After intravenous methylprednisolone therapy for two weeks, the patient fully recovered from treatment-related toxicities. After a multidisciplinary treatment (MDT) discussion and a communication with the patient, the decision was made to undergo a new fully humanized programmed death 1 (PD-1) agent, zimberelimab, combined with pazopanib for immune restart therapy. After two cycles of treatment, the patient demonstrated a partial response (PR), and the disease remained in continuous remission without any irAE at our last follow-up after 14 months’ treatment. Re-challenging with immunotherapy after irAEs is an emerging strategy that offers the potential for additional clinical benefits to previously responding patients. However, careful patient selection and monitoring are essential to maximize the safety and efficacy of this approach. Frontiers Media S.A. 2023-10-17 /pmc/articles/PMC10616240/ /pubmed/37915573 http://dx.doi.org/10.3389/fimmu.2023.1270828 Text en Copyright © 2023 He, Wang, Sun, Du and Yu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
He, Shengxiu
Wang, Liang
Sun, Yan
Du, Huakun
Yu, Xiaomin
Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
title Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
title_full Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
title_fullStr Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
title_full_unstemmed Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
title_short Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
title_sort case report: successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616240/
https://www.ncbi.nlm.nih.gov/pubmed/37915573
http://dx.doi.org/10.3389/fimmu.2023.1270828
work_keys_str_mv AT heshengxiu casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer
AT wangliang casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer
AT sunyan casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer
AT duhuakun casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer
AT yuxiaomin casereportsuccessfulimmunecheckpointinhibitorbasedrechallengeinapatientwithadvancedrenalclearcellcancer